Table 2.

Standardized incidence ratios of secondary malignancy in patients diagnosed with primary clinically localized CAP, stratified by follow-up intervals after diagnosis of primary malignancy. Bold typeface indicates p<0.05.

	Time after diagnosis of primary malignancy
	2–11 months		12–59 months		60–119 months		≥120 months		Total
	Obs/Exp	SIR (95% CI)	Obs/Exp	SIR (95% CI)	Obs/Exp	SIR (95% CI)	Obs/Exp	SIR (95% CI)	Obs/Exp	SIR (95% CI)
Thyroid	54/29.5	1.83 (1.4–2.4)	146/118	1.24 (1.0–1.5)	109/87	1.25 (1.0–1.5)	29/26	1.11 (0.7–1.6)	338/261	1.30 (1.2–1.4)
Kidney	399/160	2.49 (2.3–2.8)	712/653	1.09 (1.01–1.17)	534/491	1.09 (1–1.2)	177/152	1.16 (1–1.4)	1822/1457	1.25 (1.19–1.31)
Urinary Bladder	552/390	1.41 (1.3–1.5)	1812/1673	1.08 (1.03–1.13)	1401/1360	1.03 (0.98–1.09)	523/466	1.12 (1.0–1.2)	4288/3891	1.10 (1.07–1.14)
Colorectal	595/592	1.01 (0.9–1.1)	2308/2384	0.97 (0.93–1.01)	1507/1718	0.88 (0.83–0.92)	478/530	0.90 (0.8–0.99)	4888/5223	0.94 (0.91–0.96)
Lung and Bronchus	767/849	0.90 (0.84–.097)	2717/3446	0.79 (0.76–0.82)	2075/2550	0.81 (0.78–0.85)	631/803	0.79 (0.73–0.85)	6190/7648	0.81 (0.79–0.83)
Esophagus	72/82	0.88 (0.69–1.11)	262/332	0.79 (0.7–0.89)	221/246	0.9 (0.79–1.03)	64/76	0.84 (0.65–1.08)	619/736	0.84 (0.78–0.91)
Pancreas	132/140	0.95 (0.8–1.1)	561/586	0.96 (0.88–1.0)	407/464	0.88 (0.79–0.97)	147/156	0.95 (0.8–1.11)	1247/1345	0.93 (0.88–0.98)
Hodgkin’s Lymphoma	16/12	1.37 (0.8–2.2)	37/46	0.8 (0.6–1.1)	32/33	0.97 (0.66–1.4)	7/10	0.68 (0.3–1.4)	92/101	0.91 (0.73–1.12)
Non-Hodgkin’s Lymphoma	284/213	1.34 (1.2–1.5)	871/887	0.98 (0.92–1.1)	706/692	1.02 (0.95–1.1)	226/227	0.99 (0.87–1.1)	2087/2019	1.03 (0.99–1.08)
Leukemia	133/150	0.88 (0.74–1.1)	545/633	0.86 (0.79–0.94)	476/500	0.95 (0.87–1.04)	184/168	1.09 (0.94–1.26)	1338/1451	0.92 (0.87–0.97)